{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:27:32Z","timestamp":1765607252751,"version":"3.48.0"},"reference-count":12,"publisher":"BMJ","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gut"],"published-print":{"date-parts":[[1995,10]]},"abstract":"<jats:p>From 1979 to 1985 2435 patients having had transient ischaemic attacks (TIAs) or minor ischaemic strokes, were enrolled in the UK TIA trial and were randomised to receive either aspirin 300 mg, daily or aspirin 1200 mg or placebo. Analysis of reported upper gastrointestinal bleeding events (defined as haematemesis or melaena, or both) showed a risk of bleeding in a dose dependent manner, odds ratios (95% CI) for 300 mg of aspirin = 3.3 (1.2 to 9.0) and for 1200 mg = 6.4 (2.5 to 16.5) and, as would be expected, an increased risk of hospitalisation because of bleeding also in a dose dependent manner, odds ratio = 3.6 (0.7 to 17.2) for 300 mg and 8.7 (2.0 to 37.6) for 1200 mg. Further analysis suggested greater risks of bleeding from duodenal ulcers than gastric ulcers and that bleeding is more likely early in the course of treatment with aspirin used as secondary prevention. There was also an increased risk of lower gastrointestinal bleeding, defined as fresh blood per rectum for both doses of aspirin, odds ratio 1.8 (0.5 to 6.1) for 300 mg of aspirin, and 1.5 (0.4 to 5.3) for 1200 mg of aspirin.<\/jats:p>","DOI":"10.1136\/gut.37.4.509","type":"journal-article","created":{"date-parts":[[2007,9,18]],"date-time":"2007-09-18T17:41:31Z","timestamp":1190137291000},"page":"509-511","source":"Crossref","is-referenced-by-count":91,"title":["Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin--analysis of gastrointestinal bleeding during the UK-TIA trial."],"prefix":"10.1136","volume":"37","author":[{"given":"J","family":"Slattery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C P","family":"Warlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C J","family":"Shorrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M J","family":"Langman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1995,10,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomized trials of antiplatelet therapy - I. Prevention of death, vascular disease by prolonged anti-platelet treatment, myocardial infarction, and stoke by prolonged anti platelet therapy in various categories of patients","volume":"308","author":"Collaboration, Antiplatelet Trialists","year":"1994","unstructured":"Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - I. Prevention of death, vascular disease by prolonged anti-platelet treatment, myocardial infarction, and stoke by prolonged anti platelet therapy in various categories of patients. BMJ 1994; 308: 81-106.","journal-title":"BMJ"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0016-5085(89)80060-5","article-title":"Epidemiological evidence on the association between peptic ulceration and anti-inflammatory drug use","volume":"96","author":"Langman, M.J.S.","year":"1989","unstructured":"Langman MJS. Epidemiological evidence on the association between peptic ulceration and anti-inflammatory drug use. Gastroenterology 1989; 96: 640-6.","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(94)90185-6","article-title":"Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs","volume":"343","author":"Langman, M.J.S.; Weil, J.; Wainwright, P.; Lawson, D.H.; Rawlins, M.D.; Logan, R.F.A.","year":"1994","unstructured":"Langman MJS, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RFA, et al. Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8.","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-114-4-257","article-title":"Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons","volume":"114","author":"Griffin, M.R.; Piper, J.M.; Daugherty, JR, Snowden; M, Ray; W.A.","year":"1991","unstructured":"Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-63.","journal-title":"Ann Intern Med"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/bmj.290.6465.347","article-title":"Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage","volume":"290","author":"Langman, M.J.S.; Morgan, L.; Worrall, A.","year":"1985","unstructured":"Langman MJS, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. BMJ 1985; 290: 347-9.","journal-title":"BMJ"},{"key":"ref_6","article-title":"Statistics with confidence","author":"Gardner, M.J.; Altman, D.G.","year":"1989","unstructured":"Gardner MJ, Altman DG. Statistics with confidence. London: BMJ Publishing Group, 1989."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","article-title":"Prophylactic aspirin and risk of peptic ulcer bleeding","volume":"310","author":"Weil, J.; Colin-Jones, D.; Langman, M.J.S.; Lawson, D.; Logan, R.F.A.; Murphy, M.","year":"1995","unstructured":"Weil J, Colin-Jones D, Langman MJS, Lawson D, Logan RFA, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-30.","journal-title":"BMJ"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Steering committee of the Physicians Health Study Research Group. Final Report on the aspirin component of the ongoing physicians health study","volume":"321","year":"1989","unstructured":"Steering committee of the Physicians Health Study Research Group. Final Report on the aspirin component of the ongoing physicians health study. N Engl J Med 1989; 321: 129-35.","journal-title":"N Engl J Med"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease","volume":"336","author":"Group, The R.I.S.C.","year":"1990","unstructured":"The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-31.","journal-title":"Lancet"},{"key":"ref_10","first-page":"327","article-title":"Gastric adaptation studies in humans during continuous aspirin administration","volume":"95","author":"Graham, D.Y.; Smith, J.L.; Spjut, H.J.; Torres, E.","year":"1988","unstructured":"Graham DY, Smith JL, Spjut HJ, Torres E. Gastric adaptation studies in humans during continuous aspirin administration. Gastroenterology 1988; 95: 327-33.","journal-title":"Gastroenterology"},{"key":"ref_11","first-page":"334","article-title":"The effect of indomethacin on gastroduodenal morphology and mucosal pH gradient","volume-title":"the healthy human stomach. Gastroenterology 1990","volume":"99","author":"Shorrock, C.J.; Prescott, R.J.; Rees, W.D.W.","unstructured":"Shorrock CJ, Prescott RJ, Rees WDW. The effect of indomethacin on gastroduodenal morphology and mucosal pH gradient in the healthy human stomach. Gastroenterology 1990; 99: 334-9."},{"key":"ref_12","first-page":"349","article-title":"Second international study of infarct survival collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among","volume":"ii:","year":"1988","unstructured":"Second international study of infarct survival collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction ISIS 2. Second International Study of Infarct Survival Collaborative Group. Lancet 1988; ii: 349-60.","journal-title":"Lancet; cases of suspected acute myocardial infarction ISIS 2. Second International Study of Infarct Survival Collaborative Group"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gut.37.4.509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:23:31Z","timestamp":1765607011000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gut.37.4.509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,10]]},"references-count":12,"journal-issue":{"issue":"4","published-online":{"date-parts":[[1995,10,1]]},"published-print":{"date-parts":[[1995,10]]}},"alternative-id":["10.1136\/gut.37.4.509"],"URL":"https:\/\/doi.org\/10.1136\/gut.37.4.509","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"type":"print","value":"0017-5749"},{"type":"electronic","value":"1468-3288"}],"subject":[],"published":{"date-parts":[[1995,10]]}}}